Overcoming Irinotecan Resistance by Targeting Its Downstream Signaling Pathways in Colon Cancer

Area of Science:

• Oncology
• Cancer Biology
• Chemotherapy

Background:

• Irinotecan is a key chemotherapy for metastatic colorectal cancer (CRC).
• Current immunotherapy is effective only for a small subset of CRCs (microsatellite-instable).
• Understanding irinotecan's mechanisms is crucial for developing combination therapies.

Purpose of the Study:

• To investigate irinotecan's effects on tumor suppressor genes and oncogenes.
• To identify pathways involved in irinotecan sensitivity and resistance.
• To explore potential therapeutic targets for combination therapy in CRC.

Main Methods:

• Quantitative real-time PCR (qRT-PCR), Western blotting, immunofluorescence (IF), and RNA sequencing.
• Stable knockdown, neutralizing antibodies, and inhibitors for OPN, p53, and NF-κB.
• In vivo studies using syngeneic mouse models and allograft tumors.

Main Results:

• Suppression of OPN and NF-κB sensitized colon cancer cells to irinotecan.
• p53 inhibition did not affect SN38-regulated signaling, indicating p53-independent effects.
• Irinotecan inhibited tumor growth in mice; RNA-seq revealed NF-κB activation modulated immune/inflammatory genes, potentially causing resistance.

Conclusions:

• Targeting OPN, NF-κB, PD-L1, and ISG15 signaling may overcome irinotecan resistance in CRC.
• Irinotecan's efficacy is partly mediated through p53-independent pathways.
• Modulating immune and inflammatory responses could enhance irinotecan-based chemotherapy effectiveness.